ID   TESK1_HUMAN             Reviewed;         626 AA.
AC   Q15569; Q8IXZ8;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   12-OCT-2022, entry version 200.
DE   RecName: Full=Dual specificity testis-specific protein kinase 1;
DE            EC=2.7.12.1;
DE   AltName: Full=Testicular protein kinase 1;
GN   Name=TESK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hepatoma;
RX   PubMed=8537404; DOI=10.1074/jbc.270.52.31331;
RA   Toshima J., Ohashi K., Okano I., Nunoue K., Kishioka M., Kuma K.,
RA   Miyata T., Hirai M., Baba T., Mizuno K.;
RT   "Identification and characterization of a novel protein kinase, TESK1,
RT   specifically expressed in testicular germ cells.";
RL   J. Biol. Chem. 270:31331-31337(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH YWHAB.
RX   PubMed=11555644; DOI=10.1074/jbc.m104620200;
RA   Toshima J.Y., Toshima J., Watanabe T., Mizuno K.;
RT   "Binding of 14-3-3beta regulates the kinase activity and subcellular
RT   localization of testicular protein kinase 1.";
RL   J. Biol. Chem. 276:43471-43481(2001).
RN   [6]
RP   INTERACTION WITH SPRY4.
RX   PubMed=12027893; DOI=10.1046/j.1432-1033.2002.02921.x;
RA   Leeksma O.C., van Achterberg T.A.E., Tsumura Y., Toshima J., Eldering E.,
RA   Kroes W.G.M., Mellink C., Spaargaren M., Mizuno K., Pannekoek H.,
RA   de Vries C.J.M.;
RT   "Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual
RT   specificity kinase TESK1.";
RL   Eur. J. Biochem. 269:2546-2556(2002).
RN   [7]
RP   FUNCTION, INTERACTION WITH SPRY4, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-175.
RX   PubMed=15584898; DOI=10.1042/bj20041181;
RA   Tsumura Y., Toshima J., Leeksma O.C., Ohashi K., Mizuno K.;
RT   "Sprouty-4 negatively regulates cell spreading by inhibiting the kinase
RT   activity of testicular protein kinase.";
RL   Biochem. J. 387:627-637(2005).
RN   [8]
RP   INTERACTION WITH PARVA.
RX   PubMed=15817463; DOI=10.1074/jbc.m500752200;
RA   LaLonde D.P., Brown M.C., Bouverat B.P., Turner C.E.;
RT   "Actopaxin interacts with TESK1 to regulate cell spreading on
RT   fibronectin.";
RL   J. Biol. Chem. 280:21680-21688(2005).
RN   [9]
RP   INTERACTION WITH SPRED1.
RX   PubMed=17974561; DOI=10.1074/jbc.m705457200;
RA   Chandramouli S., Yu C.Y., Yusoff P., Lao D.H., Leong H.F., Mizuno K.,
RA   Guy G.R.;
RT   "Tesk1 interacts with Spry2 to abrogate its inhibition of ERK
RT   phosphorylation downstream of receptor tyrosine kinase signaling.";
RL   J. Biol. Chem. 283:1679-1691(2008).
RN   [10]
RP   INTERACTION WITH SPRED1.
RX   PubMed=18216281; DOI=10.1091/mbc.e07-07-0730;
RA   Johne C., Matenia D., Li X.Y., Timm T., Balusamy K., Mandelkow E.M.;
RT   "Spred1 and TESK1--two new interaction partners of the kinase MARKK/TAO1
RT   that link the microtubule and actin cytoskeleton.";
RL   Mol. Biol. Cell 19:1391-1403(2008).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=25849865; DOI=10.1038/ncomms7781;
RA   Kim J., Jo H., Hong H., Kim M.H., Kim J.M., Lee J.K., Heo W.D., Kim J.;
RT   "Actin remodelling factors control ciliogenesis by regulating YAP/TAZ
RT   activity and vesicle trafficking.";
RL   Nat. Commun. 6:6781-6781(2015).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=30115939; DOI=10.1038/s41598-018-30115-3;
RA   Wang L., Buckley A.F., Spurney R.F.;
RT   "Regulation of cofilin phosphorylation in glomerular podocytes by testis
RT   specific kinase 1 (TESK1).";
RL   Sci. Rep. 8:12286-12286(2018).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] TYR-539.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-539 AND SER-574.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity protein kinase activity catalyzing
CC       autophosphorylation and phosphorylation of exogenous substrates on both
CC       serine/threonine and tyrosine residues (By similarity). Regulates the
CC       cellular cytoskeleton by enhancing actin stress fiber formation via
CC       phosphorylation of cofilin and by preventing microtubule breakdown via
CC       inhibition of TAOK1/MARKK kinase activity (By similarity). Inhibits
CC       podocyte motility via regulation of actin cytoskeletal dynamics and
CC       phosphorylation of CFL1 (By similarity). Positively regulates integrin-
CC       mediated cell spreading, via phosphorylation of cofilin
CC       (PubMed:15584898). Suppresses ciliogenesis via multiple pathways;
CC       phosphorylation of CFL1, suppression of ciliary vesicle directional
CC       trafficking to the ciliary base, and by facilitating YAP1 nuclear
CC       localization where it acts as a transcriptional corepressor of the
CC       TEAD4 target genes AURKA and PLK1 (PubMed:25849865). Probably plays a
CC       central role at and after the meiotic phase of spermatogenesis (By
CC       similarity). {ECO:0000250|UniProtKB:O70146,
CC       ECO:0000250|UniProtKB:Q63572, ECO:0000269|PubMed:15584898,
CC       ECO:0000269|PubMed:25849865}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Activated by autophosphorylation on Ser-220.
CC       Kinase activity is inhibited by SPRED1. {ECO:0000250|UniProtKB:Q63572}.
CC   -!- SUBUNIT: Interacts (via both C- and N-termini) with SPRY4 (via C-
CC       terminus); the interaction inhibits TESK1 kinase activity
CC       (PubMed:12027893, PubMed:15584898). Interacts with TAOK1; the
CC       interaction inhibits TAOK1 kinase activity (By similarity). Interacts
CC       (via C-terminus) with SPRED1 (via C-terminus); the interaction inhibits
CC       TESK1 kinase activity (PubMed:18216281). Interacts (via C-terminus)
CC       with PARVA/PARVIN (via C-terminus); the interaction inhibits TESK1
CC       kinase activity (PubMed:15817463). Interacts with YWHAB/14-3-3 beta;
CC       the interaction is dependent on the phosphorylation of TESK1 Ser-437
CC       and inhibits TESK1 kinase activity (PubMed:11555644). Interacts with
CC       SPRY1, SPRY3 and SPRED2 (PubMed:17974561). Interacts (via C-terminus)
CC       with SPRY2 (via C-terminus); the interaction disrupts SPRY2 interaction
CC       with PPP2CA/PP2A-C, possibly by vesicular sequestration of SPRY2
CC       (PubMed:17974561). Therefore dephosphorylation of SPRY2 by the
CC       serine/threonine-protein phosphatase 2A (PP2A) holoenzyme is lost,
CC       inhibiting its interaction with GRB2 (PubMed:17974561).
CC       {ECO:0000250|UniProtKB:Q63572, ECO:0000269|PubMed:11555644,
CC       ECO:0000269|PubMed:12027893, ECO:0000269|PubMed:15584898,
CC       ECO:0000269|PubMed:15817463, ECO:0000269|PubMed:17974561,
CC       ECO:0000269|PubMed:18216281}.
CC   -!- INTERACTION:
CC       Q15569; Q9C004: SPRY4; NbExp=4; IntAct=EBI-354852, EBI-354861;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15584898}.
CC       Cytoplasm, perinuclear region {ECO:0000250|UniProtKB:Q63572}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:25849865}. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:Q63572}. Note=Colocalizes with SPRY4 in
CC       vesicular spots in the cytoplasm (PubMed:15584898). Localized to F-
CC       actin-rich lamellipodia at the cell periphery following fibronectin-
CC       mediated cell adhesion of Schwann cells (By similarity).
CC       {ECO:0000250|UniProtKB:Q63572, ECO:0000269|PubMed:15584898}.
CC   -!- TISSUE SPECIFICITY: Expressed in podocytes and renal tubular cells in
CC       the kidney (at protein level). {ECO:0000269|PubMed:30115939}.
CC   -!- DOMAIN: The extracatalytic C-terminal part is highly rich in proline
CC       residues.
CC   -!- PTM: Autophosphorylated on serine and tyrosine residues.
CC       {ECO:0000250|UniProtKB:Q63572}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D50863; BAA09459.1; -; mRNA.
DR   EMBL; AL357874; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58375.1; -; Genomic_DNA.
DR   EMBL; BC038448; AAH38448.1; -; mRNA.
DR   EMBL; BC067130; AAH67130.1; -; mRNA.
DR   CCDS; CCDS6580.1; -.
DR   RefSeq; NP_001305159.1; NM_001318230.1.
DR   RefSeq; NP_006276.2; NM_006285.2.
DR   AlphaFoldDB; Q15569; -.
DR   SMR; Q15569; -.
DR   BioGRID; 112875; 15.
DR   IntAct; Q15569; 21.
DR   MINT; Q15569; -.
DR   STRING; 9606.ENSP00000481045; -.
DR   BindingDB; Q15569; -.
DR   ChEMBL; CHEMBL5604; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q15569; -.
DR   GuidetoPHARMACOLOGY; 2239; -.
DR   iPTMnet; Q15569; -.
DR   PhosphoSitePlus; Q15569; -.
DR   BioMuta; TESK1; -.
DR   DMDM; 209572684; -.
DR   EPD; Q15569; -.
DR   jPOST; Q15569; -.
DR   MassIVE; Q15569; -.
DR   PaxDb; Q15569; -.
DR   PeptideAtlas; Q15569; -.
DR   PRIDE; Q15569; -.
DR   ProteomicsDB; 60637; -.
DR   Antibodypedia; 2068; 152 antibodies from 26 providers.
DR   DNASU; 7016; -.
DR   Ensembl; ENST00000336395.6; ENSP00000338127.5; ENSG00000107140.16.
DR   Ensembl; ENST00000620767.4; ENSP00000481045.1; ENSG00000107140.16.
DR   GeneID; 7016; -.
DR   KEGG; hsa:7016; -.
DR   MANE-Select; ENST00000336395.6; ENSP00000338127.5; NM_006285.3; NP_006276.2.
DR   UCSC; uc003zxa.4; human.
DR   CTD; 7016; -.
DR   DisGeNET; 7016; -.
DR   GeneCards; TESK1; -.
DR   HGNC; HGNC:11731; TESK1.
DR   HPA; ENSG00000107140; Low tissue specificity.
DR   MIM; 601782; gene.
DR   neXtProt; NX_Q15569; -.
DR   OpenTargets; ENSG00000107140; -.
DR   PharmGKB; PA36448; -.
DR   VEuPathDB; HostDB:ENSG00000107140; -.
DR   eggNOG; ENOG502QTCP; Eukaryota.
DR   GeneTree; ENSGT00940000157807; -.
DR   HOGENOM; CLU_018577_0_0_1; -.
DR   InParanoid; Q15569; -.
DR   OMA; SPPTWGD; -.
DR   OrthoDB; 219904at2759; -.
DR   PhylomeDB; Q15569; -.
DR   TreeFam; TF318014; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q15569; -.
DR   Reactome; R-HSA-446388; Regulation of cytoskeletal remodeling and cell spreading by IPP complex components.
DR   SignaLink; Q15569; -.
DR   SIGNOR; Q15569; -.
DR   BioGRID-ORCS; 7016; 32 hits in 1114 CRISPR screens.
DR   ChiTaRS; TESK1; human.
DR   GeneWiki; TESK1; -.
DR   GenomeRNAi; 7016; -.
DR   Pharos; Q15569; Tchem.
DR   PRO; PR:Q15569; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q15569; protein.
DR   Bgee; ENSG00000107140; Expressed in right testis and 177 other tissues.
DR   Genevisible; Q15569; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0051650; P:establishment of vesicle localization; IMP:UniProtKB.
DR   GO; GO:1902018; P:negative regulation of cilium assembly; IMP:UniProtKB.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; ISS:UniProtKB.
DR   GO; GO:0031953; P:negative regulation of protein autophosphorylation; ISS:ARUK-UCL.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; ISS:ARUK-UCL.
DR   GO; GO:0090521; P:podocyte cell migration; ISS:UniProtKB.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISS:ARUK-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0032880; P:regulation of protein localization; ISS:ARUK-UCL.
DR   GO; GO:0007283; P:spermatogenesis; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR015782; TESK1.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   PANTHER; PTHR46485:SF3; PTHR46485:SF3; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell projection; Cytoplasm; Cytoskeleton; Kinase; Magnesium;
KW   Manganese; Metal-binding; Methylation; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN           1..626
FT                   /note="Dual specificity testis-specific protein kinase 1"
FT                   /id="PRO_0000086746"
FT   DOMAIN          57..314
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..41
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          331..373
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          419..524
FT                   /note="Required for interaction with YWHAB"
FT                   /evidence="ECO:0000250|UniProtKB:Q63572"
FT   REGION          423..488
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          527..626
FT                   /note="Required for interaction with SPRED1 and SPRY2.
FT                   Required for TESK1-mediated dephosphorylation of SPRY2 and
FT                   SPRY2 inhibition of ERK phosphorylation"
FT                   /evidence="ECO:0000250|UniProtKB:Q63572"
FT   REGION          527..624
FT                   /note="Required for interaction with PARVA"
FT                   /evidence="ECO:0000250|UniProtKB:Q63572"
FT   REGION          529..564
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        8..22
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        175
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         63..71
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         86
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         220
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q63572"
FT   MOD_RES         338
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:O70146"
FT   VARIANT         539
FT                   /note="H -> Y (in breast cancer samples; infiltrating
FT                   ductal carcinoma; somatic mutation; dbSNP:rs1373248755)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_035638"
FT   VARIANT         574
FT                   /note="G -> S (in dbSNP:rs55673450)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041213"
FT   MUTAGEN         175
FT                   /note="D->A: Abolishes inhibition of SPRY4-mediated
FT                   repression of cell spreading. No effect on interaction with
FT                   SPRY4 or colocalization with SPRY4 at vesicular spots in
FT                   the cytoplasm."
FT                   /evidence="ECO:0000269|PubMed:15584898"
FT   CONFLICT        43
FT                   /note="A -> V (in Ref. 1; BAA09459)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   626 AA;  67684 MW;  32F78E5E6AEDB0E5 CRC64;
     MAGERPPLRG PGPGPGEVPG EGPPGPGGTG GGPGRGRPSS YRALRSAVSS LARVDDFHCA
     EKIGAGFFSE VYKVRHRQSG QVMVLKMNKL PSNRGNTLRE VQLMNRLRHP NILRFMGVCV
     HQGQLHALTE YMNGGTLEQL LSSPEPLSWP VRLHLALDIA RGLRYLHSKG VFHRDLTSKN
     CLVRREDRGF TAVVGDFGLA EKIPVYREGA RKEPLAVVGS PYWMAPEVLR GELYDEKADV
     FAFGIVLCEL IARVPADPDY LPRTEDFGLD VPAFRTLVGD DCPLPFLLLA IHCCNLEPST
     RAPFTEITQH LEWILEQLPE PAPLTRTALT HNQGSVARGG PSATLPRPDP RLSRSRSDLF
     LPPSPESPPN WGDNLTRVNP FSLREDLRGG KIKLLDTPSK PVLPLVPPSP FPSTQLPLVT
     TPETLVQPGT PARRCRSLPS SPELPRRMET ALPGPGPPAV GPSAEEKMEC EGSSPEPEPP
     GPAPQLPLAV ATDNFISTCS SASQPWSPRS GPVLNNNPPA VVVNSPQGWA GEPWNRAQHS
     LPRAAALERT EPSPPPSAPR EPDEGLPCPG CCLGPFSFGF LSMCPRPTPA VARYRNLNCE
     AGSLLCHRGH HAKPPTPSLQ LPGARS
//
